verapamil has been researched along with atenolol in 206 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (17.96) | 18.7374 |
| 1990's | 42 (20.39) | 18.2507 |
| 2000's | 61 (29.61) | 29.6817 |
| 2010's | 55 (26.70) | 24.3611 |
| 2020's | 11 (5.34) | 2.80 |
| Authors | Studies |
|---|---|
| Gubernator, K; Kansy, M; Senner, F | 1 |
| Danelian, E; Hämäläinen, MD; Hansson, A; Karlén, A; Karlsson, R; Lennernäs, H; Löfâs, S; Winiwarter, S | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Caron, G; Ermondi, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Conradi, R; Lee, PH; Shanmugasundaram, V | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Bode, ML; Gravestock, D; Hoppe, HC; Khan, T; Moleele, SS; Nkabinde, LA; Pelly, SC; Steenkamp, PA; van der Westhuyzen, CW | 1 |
| Brea, J; Cadavid, MI; Campillo, NE; Ceballos, P; Gil, C; Loza, MI; Martínez, A; Moro, MA; Pérez, C; Pérez, DI; Perez-Castillo, A; Redondo, M; Val, C; Zarruk, JG | 1 |
| Andrisano, V; Bolognesi, ML; Carloni, P; Cavalli, A; Chiriano, G; De Simone, A; Legname, G; Mancini, F; Martinez, A; Perez, DI; Roberti, M | 1 |
| Alonso-Gil, S; Campillo, NE; Castro, A; Encinas, A; Gil, C; Martinez, A; Morales-Garcia, JA; Palomo, V; Perez, C; Perez, DI; Perez-Castillo, A; Soteras, I | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Alonso-Gil, S; Chavarría, C; Gil, C; Morales Garcia, JA; Pérez, C; Perez, DI; Pérez-Castillo, A; Porcal, W; Souza, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bello, ML; Gil, C; Kraemer, BC; Lecourtois, M; Liachko, NF; Martinez, A; Miguel, L; Perez, C; Perez, DI; Redondo, M; Salado, IG | 1 |
| Augustijns, P; De Coen, LM; Jatczak, M; Keemink, J; Muylaert, K; Stevens, CV; Wuyts, B | 1 |
| Huang, L; Li, X; Meng, F; Miao, H; Sun, Y | 1 |
| Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š | 1 |
| Bloomer, WD; Chatelain, E; Ioset, JR; Kaiser, M; O'Shea, IP; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR | 1 |
| Bloomer, WD; Kaiser, M; O'Shea, IP; Papadopoulou, MV; Rosenzweig, HS; Wilkinson, SR | 1 |
| Chang, S; Gao, W; Gao, YX; Liao, H; Pang, T; Qiu, WW; Wang, YJ; Wang, YY; Xu, Y; Xu, YZ; Yang, LF; Yu, LG; Zhang, LY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Kandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 1 |
| Guo, QL; Huang, SL; Huang, ZS; Li, D; Liu, ZQ; Ou, TM; Tan, JH; Wang, HG; Wang, N; Wu, JQ; Xia, CL | 1 |
| Alliston, KR; Bowlin, TL; Butler, MM; Cardinale, SC; Chang, KO; Galasiti Kankanamalage, AC; Groutas, WC; Kim, Y; Rathnayake, AD | 1 |
| Campillo, NE; Geiger, L; Gil, C; González, S; Li, L; Martinez, A; Morales, AV; Perez, DI; Salado, IG; Sebastián-Pérez, V; Zaldivar-Diez, J | 1 |
| Albert, DH; Bui, MH; Edalji, RP; Elmore, SW; Faivre, EJ; Fang, G; Fidanze, SD; Gao, W; Hasvold, LA; Huang, X; Hutchins, CW; Kati, WM; Li, L; Lin, X; Liu, D; Magoc, TJ; Mantei, RA; Martin, R; McDaniel, KF; Park, CH; Pratt, JK; Rajaraman, G; Shen, JJ; Shen, Y; Sheppard, GS; Soltwedel, T; Sun, CC; Wang, L; Wang, R; Warder, SE; Wilcox, D; Wong, S | 1 |
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
| Ganeshpurkar, A; Gupta, SK; Gutti, G; Krishnamurthy, S; Kumar, D; Modi, G; Singh, SK | 1 |
| Cleghorn, LAT; Davis, S; Epemolu, O; Ferguson, L; Green, SR; Guijarro, L; Hipskind, P; Huggett, M; Korkegian, A; Kumar, A; Lopez Moure, A; Masquelin, T; Odingo, J; Parish, T; Ray, PC; Read, KD; Riley, J; Rullas, J; Scullion, P; Shishikura, Y; Smith, A; Turner, P; Wescott, H; Wilson, C; Wyatt, PG; Zuccotto, F | 1 |
| Cini, E; De Santis, R; Giannini, G; Manera, F; Manetti, F; Milazzo, FM; Pace, S; Petricci, E; Stasi, MA; Tallarico, C; Vesci, L | 1 |
| Rai, SN; Shankar, S; Sharma, P; Shrivastava, SK; Singh, SP; Srivastava, P; Srivastava, RK; Tripathi, PN | 1 |
| An, B; Hu, J; Huang, L; Li, X; Li, Z; Pan, T | 1 |
| Sharma, P; Shrivastava, SK; Srivastava, P; Tripathi, PN | 1 |
| Dash, AK; Dhulap, A; Haider, S; Kumar, D; Mukherjee, D | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
| Barbosa, G; Ceschi, MA; Dantas, RF; Dardenne, LE; de Salles, CMC; Guedes, IA; Lima, LM; Lopes, JPB; Lüdtke, DS; Ruaro, TC; Senger, MR; Silva, L; Silva-Jr, FP; Zimmer, AR | 1 |
| Esaki, T; Kawashima, H; Komura, H; Kuroda, M; Mizuguchi, K; Natsume-Kitatani, Y; Ohashi, R; Watanabe, R | 1 |
| Chao, MW; Lai, MJ; Liou, JP; Liu, YM; Pan, SL; Teng, CM; Tu, HJ; Wu, CH; Wu, YW; Yu, SC | 1 |
| Chen, H; Ding, H; Gao, Y; Jiang, X; Liu, W; Liu, X; Tian, L; Xu, Z; Zhao, Q | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
| Ahuja, VT; Allen, J; Bristow, LJ; Bronson, JJ; Brown, JM; Camac, D; Dandapani, K; Dokania, M; Dzierba, CD; Easton, A; Elavazhagan, S; Gulianello, M; Hamman, BD; Hartz, RA; Hunihan, L; Kiefer, SE; Kostich, W; Kumar, CMV; Lewis, M; Lippy, JS; Macor, JE; Muckelbauer, JK; Nara, SJ; Pattipati, SN; Rajamani, R; Surti, N | 1 |
| Chaikuad, A; de Lago, E; Gil, C; Gomez-Almeria, M; Gonzalo-Consuegra, C; Knapp, S; Lietha, D; Martín-Requero, A; Martinez, A; Martínez-González, L; Monti, B; Nozal, V; Palomo, V; Pérez-Cuevas, E; Petralla, S; Ramírez, D; Santana, P | 1 |
| Jaiswal, S; Raja Ayyannan, S; Tiwari, V; Uniyal, A | 1 |
| Bandopadhyay, P; Das, N; Dastidar, UG; Ganguly, D; Pal, S; Rahaman, O; Roy, S; Sinha, BP; Talukdar, A | 1 |
| Hayduk, K; Hepp, A; Maisch, B; Raff, U | 1 |
| Gerstenblith, G | 2 |
| Abiko, Y; Ichihara, K; Nasa, Y; Yoshida, R | 1 |
| Mooij, JM; Schiffers, PM; van Baak, MA | 1 |
| Lipworth, BJ; Pringle, TH; Wheeldon, NM | 1 |
| Durel, LA; Hayashi, PJ; Schneiderman, N; Weidler, DJ | 1 |
| Amery, A; Fagard, R; Lijnen, P; Vanhees, L | 1 |
| Fagher, B; Herbertsson, P | 1 |
| Haunsø, S; Sejrsen, P; Svendsen, JH | 1 |
| Bailly, D; Dimas, A; Frierson, J; Shultz, T; Sund, S | 1 |
| Hollinrake, K; Hopkinson, ND; Hui, KP; Smith, MP | 1 |
| Avenant, JC; Meyer, EC; Sommers, DK | 1 |
| Alegría, E; Castello, MJ; García, A; Soria, F; Valdés, M; Vicente, T | 1 |
| Becker, LC; Gerstenblith, G; Gottlieb, SO; Schulman, SP; Weisfeldt, ML; Weiss, JL; Woodruff, KM | 1 |
| Gerstenblith, G; Schulman, SP | 1 |
| Curry, C; Gray, J; Hollifield, J; Kong, BW; Saunders, E; Schoenberger, J; Sowers, JR; Vertes, V; Weir, MR; Zemel, MB | 1 |
| Baume, RM; Croog, SH; Kong, BW; Levine, S; Saunders, E; Weir, MR | 1 |
| Bandyopadhyay, S; Klaunig, JE; Somani, P | 1 |
| Lewis, RV; McDevitt, DG; McMurray, J | 1 |
| Grably, S; Rossi, A; Verdys, M | 1 |
| Amery, A; Fagard, R; Vanhees, L | 2 |
| Ernst, JE; Gerzer, R; Haufe, MC; Heim, JM; Theisen, K; Weil, J | 1 |
| Cariello, L; Nelson, L | 1 |
| Bhandari, K; Misra, M; Puri, VK; Thakur, R | 1 |
| McGourty, JC; Silas, JH; Solomon, SA | 1 |
| Henry, M; Kay, MM; Viccellio, P | 1 |
| Barrett, JA; Pruss, TP; Smith, RD; Wolf, PS | 1 |
| Dargie, HJ; Henderson, E; Herrick, AL; McInnes, GT; McLenachan, JM | 1 |
| Kadish, AH; Kou, WH; Kushner, JA; Morady, F; Schmaltz, S; Toivonen, LK | 1 |
| Custro, N; Scafidi, V | 1 |
| Edmonds, D; Förster, E; Siegenthaler, W; Vetter, W; Wehling, M | 1 |
| Harper, RW; Harrison, PM; Keech, AC; McLean, AJ; Pitt, A | 1 |
| Broustet, JP; Douard, H; Mora, B; Sermon, F | 1 |
| Escudero, J; Hernandez, H; Martinez, F | 1 |
| Aitchison, T; Dargie, HJ; Elliott, AT; Findlay, IN; Gillen, G; MacLeod, K | 1 |
| Bhandari, K; Misra, M; Thakur, R | 1 |
| Bailey, BP; Duggin, GG; Fletcher, PJ; Hall, B; Horvath, JS; Tiller, D | 1 |
| Harper, RW; Harrison, PM; Knight, R; McLean, AJ | 1 |
| Aiello, P; Ceci, V; Di Mario, F; Fiorella, AT; Longo, A; Masini, V | 1 |
| De Rábago, P; Espín, A; Ramírez, M; Sánchez Cascos, A | 1 |
| Himori, N; Ishimori, T; Iwamura, M; Izumi, A; Makino, M; Yasuda, K | 1 |
| Briscoe, MG; Halliday, SE; Smith, HJ; Snow, HM | 1 |
| Fitzsimons, TJ; Holt, D; Johnston, A; Warrington, SJ | 1 |
| Agostoni, PG; Della Bella, P; Fiorentini, C; Grazi, S; Guazzi, MD; Loaldi, A; Pepi, M | 1 |
| Birkenhäger, WH; de Leeuw, PW; van Soest, GA | 1 |
| Lessem, J | 1 |
| Hutchison, SJ; Lakhdar, A; Lorimer, AR; McAlpine, SG | 1 |
| McGourty, JC; Silas, JH | 1 |
| Dobbs, RJ; Phillips, RJ; Robinson, BF | 1 |
| Georgiev, S; Khadzhipetrov, N | 1 |
| Jewitt, DE | 1 |
| Simonsen, S | 1 |
| Sanchez-Cascos, A | 1 |
| Gil-Extremera, B; González-Gómez, L; Luna del Castillo, JD; Maldonado-Martín, A; Rubio-Luengo, MA | 1 |
| De Clerck, F; Lu, HR; Remeysen, P | 1 |
| Gómez Pajuelo, C; Gómez Sánchez, MA; Lombera Romero, F; Marín Ruiz, R; Sáenz de la Calzada, C; Sanz Julve, M; Tascón Pérez, J | 1 |
| Bretnall, AE; Clarke, GS | 1 |
| Beaulieu, M; Cléroux, J; Kouamé, N; Lacourcière, Y | 1 |
| Nagatomo, T; Shibata, A; Shimada, K; Tsuchihashi, H; Wakabayashi, H; Watanabe, K | 1 |
| Beaulieu, M; Cléroux, J; Lacourcière, Y; Lemieux, SC | 1 |
| Amado, P; Araújo, V; Carmona, J; Castanheira, J; Nazaré, J | 1 |
| Gertner, SB; Hey, JA; McLeod, RL | 1 |
| Lawrenson, JB; Millar, RN; Okreglicki, AM | 1 |
| de Leeuw, PW; Notter, T; Zilles, P | 1 |
| Bakris, GL; Copley, JB; Mangrum, A; Sadler, R; Vicknair, N | 1 |
| Cholewa, M; Gralec, M; Piusińska-Macoch, A; Sułek, K | 1 |
| Bossi, M; Tiberti, G | 1 |
| Berg, S; Kalman, S; Lisander, B | 1 |
| Bucci, A; Costantini, F; Cuccurullo, F; Lapenna, D; Mezzetti, A; Pierdomenico, SD | 1 |
| Black, HR; Elliott, WJ; Fakouhi, TD; Grambsch, P; Grandits, G; Grimm, RH; Hansson, L; Lacoucière, Y; Muller, J; Neaton, JD; Sleight, P; Weber, MA; White, WB; Williams, G; Wittes, J; Zanchetti, A | 1 |
| Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P | 1 |
| Lercher, P; Liebmann, P; Lindner, W; Maier, R; Sakotnik, A; Stoschitzky, K; Zweiker, R | 1 |
| Alov, P; Kastelova, A; Koleva, M | 1 |
| Ford, MD; Kerns, WP; Kline, JA; Tomaszewski, CA; Yuan, TH | 1 |
| Gómez Guindal, JA; González Lama, I; González Maqueda, I | 1 |
| Anderson, R; Hollenberg, NK; Williams, GH | 1 |
| Frishman, W; Glasser, SP; Johnson, MF; Stone, P; White, WB | 1 |
| Hattori, K; Hirakawa, Y; Ichihashi, R; Kei, M; Matsubara, K; Saburi, Y; Sakurai, H; Tsukamoto, H; Yokouchi, K | 1 |
| Crespi, CL; Fox, L; Hu, M; Steimel, DT; Stocker, P | 1 |
| Dohmoto, H; Hashimoto, K; Sugiyama, A; Takahara, A; Yoshimoto, R | 1 |
| Dall'Anese, C; García de Vinuesa, S; Gómez-Campderá, F; Luño, J; Ridao, N; Sánchez, M; Valderrábano, F | 1 |
| Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A | 1 |
| Cominacini, L; Ferrannini, E; Franzoni, F; Fratta-Pasini, A; Galetta, F; Garbin, U; Natali, A; Pucciarelli, A; Quiñones-Galvan, A | 1 |
| Aamar, S; Ben-Ishay, D; Bursztyn, M; Ghanem, J; Perk, G | 1 |
| Faller, J; Hess, B | 1 |
| Ciociaro, D; Ferrannini, E; Franzoni, F; Masoni, A; Natali, A; Pucciarelli, A; Quiñones-Galvan, A | 1 |
| Beck, K; Holzgreve, H; Janka, HU; Nakov, R | 1 |
| Fitilev, SB; Lepakhin, VK; Levin, AM; Oganov, RG; Sytchev, EN; Titarova, YY | 1 |
| Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ | 1 |
| Bass, EB; Tamariz, LJ | 1 |
| Addario, C; Antonelli, M; Cavallaro, F; Ferro, G; Gallizzi, F; Sandroni, C | 1 |
| Amidon, GL; Barends, DM; Junginger, HE; Midha, KK; Möller, H; Olling, M; Shah, VP; Vogelpoel, H; Welink, J | 1 |
| Bakris, GL; Cooper-DeHoff, R; Erdine, S; Gaxiola, E; Mancia, G; Messerli, FH; Pepine, CJ | 1 |
| Cooper-DeHoff, R; Elliott, WJ; Hewkin, AC; Kupfer, S; Pepine, CJ | 1 |
| Karpov, IuA | 1 |
| Fomin, VV; Moiseev, SV | 1 |
| Dainese, F; Maggioni, F; Mainardi, F; Ruffatti, S; Zanchin, G | 1 |
| Benetos, A; Coca, A; Conti, CR; Cooper-DeHoff, RM; Gaxiola, E; Handberg, E; Hewkin, AC; Kolloch, RE; Kowey, PR; Kupfer, S; Mancia, G; Pepine, CJ; Sleight, P; Tavazzi, L | 1 |
| Lopez, LM; Pepine, CJ; Ried, LD; Sauer, BC; Taylor, MD; Tueth, MJ | 1 |
| Aranda, JM; Cangiano, JL; Conti, CR; Cooper-DeHoff, RM; Garcia-Barreto, D; Gaxiola, E; Hewkin, A; Pepine, CJ | 1 |
| Benetos, A; Champion, A; Conti, CR; Hewkin, AC; Kolloch, R; Kupfer, S; Mancia, G; Messerli, FH; Pepine, CJ | 1 |
| Barthelet, M; Baumann, C; Bonnet, D; Chevallier, B; Collignon, P; Dulac, Y; Edouard, T; Faivre, L; Germain, D; Jondeau, G; Khau Van Kien, P; Lacombe, D; Ladouceur, M; Leheup, B; Lemerrer, M; Lupoglazoff, JM; Magnier, S; Muti, C; Plauchu, PH; Raffestin, B; Sassolas, F; Schleich, JM; Sidi, D; Themar-Noël, C; Varin, J; Wolf, JE | 1 |
| Bakris, GL; Cohen, JD; Cooper-Dehoff, R; Erdine, S; Hewkin, AC; Kupfer, S; Messerli, FH; Pepine, CJ | 1 |
| Blagova, OV; Nedostup, AV | 1 |
| Cai, Y; Jia, J; Li, S; Liu, G; Liu, Y; Pan, C; Ren, J; Yu, C | 1 |
| Croft, SL; Mansor, SM; Nair, NK; Navaratnam, V; Ramanathan, S; Sattar, MA; Venkatesh, G | 1 |
| Sica, DA | 1 |
| Bangalore, S; Champion, A; Cooper-Dehoff, RM; Messerli, FH; Pepine, CJ; Uretsky, S; Zhou, Q | 1 |
| Celebi, O; Kilic, T; Komsuoglu, B; Kozdag, G; Sahin, T; Ural, D; Ural, E | 1 |
| Benetos, A; Champion, A; Coca, A; Cooper-DeHoff, RM; Messerli, FH; Pepine, CJ; Zhou, Q | 1 |
| Feihl, F; Gojanovic, B; Liaudet, L; Waeber, B | 1 |
| Cooper-Dehoff, RM; Gong, Y; Johnson, JA; Langaee, TY; Pacanowski, MA; Pepine, CJ; Schork, NJ; Shriver, MD | 1 |
| Bacher, PH; Bangalore, S; Champion, A; Cohen, JD; Kowey, P; Mancia, G; Messerli, FH; Pepine, CJ; Sleight, P; Zhou, Q | 1 |
| Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ | 1 |
| Cooper-Dehoff, RM; Johnson, JA; Pacanowski, MA; Pepine, CJ; Zineh, I | 1 |
| Borchardt, RT; Mudra, DR | 1 |
| Cooper-Dehoff, RM; Gerhard, T; Gong, Y; Handberg, EM; Johnson, JA; Pepine, CJ; Ried, LD | 1 |
| Borchardt, RT; Jin, JY; Mudra, DR | 1 |
| Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q | 1 |
| DE Magalhaes, LP; Fagundes, A; Russo, M; Xavier, E | 1 |
| Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q | 1 |
| Beitelshees, AL; Cooper-DeHoff, RM; Gong, Y; Johnson, JA; Langaee, TY; Moss, JI; Navare, H; Pepine, CJ; Sadee, W; Schork, NJ; Wang, D; Wessel, J | 1 |
| Weber, MA | 1 |
| Cooper-DeHoff, RM; Johnson, JA; Martin, MA; Pacanowski, MA; Pepine, CJ; Price, ET; Zineh, I | 1 |
| Furutani, K; Inanobe, A; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Gong, Y; Hingorani, AD; Humphries, SE; Johnson, JA; Kumari, M; Newman, LC; Papp, AC; Pepine, CJ; Pinsonneault, JK; Sadee, W; Shah, S; Talmud, PJ; Wang, D | 1 |
| Cockcroft, J; Dunstan, F; Fagenello, G; Fraser, AG; Kenny, D; Nelson, M; Stuart, G; Williams, A; Wilson, D | 1 |
| Bailey, KR; Beitelshees, AL; Boerwinkle, EA; Chapman, AB; Cooper-DeHoff, RM; Del-Aguila, JL; Gong, Y; Gums, JG; Johnson, JA; Karnes, JH; Langaee, TY; McDonough, CW; Pepine, CJ; Turner, ST; Vo, TT | 1 |
| Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gawronski, BE; Gong, Y; Gums, JG; Johnson, JA; Langaee, TY; Liggett, SB; Lobmeyer, MT; Pepine, CJ; Turner, ST; Vandell, AG | 1 |
| Bertera, FM; Chiappetta, D; Del Mauro, JS; Höcht, C; Lovera, V; Polizio, AH; Taira, CA | 1 |
| Bavry, AA; Cooper-DeHoff, RM; Denardo, SJ; Farsang, C; Gong, Y; Handberg, EM; Keltai, M; Mancia, G; Messerli, FH; Pepine, CJ; Szirmai, L | 1 |
| Fan, W; Fang, W; Fu, Y; He, S; Huang, L; Li, B; Li, X; Li, Y; Shang, E; Zhang, Y | 1 |
| Bailey, KR; Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Johnson, JA; Kubo, M; Magvanjav, O; McDonough, CW; Pepine, CJ; Tanaka, T; Turner, ST | 1 |
| Andrews, LM; Koch, BCP; van der Nagel, BCH; van Domburg, B | 1 |
| Fletcher, S; Gharanei, M; James, RS; Maddock, H; Wallis, R | 1 |
| Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM | 1 |
9 review(s) available for verapamil and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Hemodynamic effects of newer antiarrhythmic drugs.
Topics: Acebutolol; Amiodarone; Anilides; Animals; Anti-Arrhythmia Agents; Atenolol; Benzeneacetamides; Disopyramide; Dogs; Hemodynamics; Humans; Mexiletine; Piperidines; Tocainide; Verapamil | 1980 |
[Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chlorthalidone; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Drug Tolerance; Humans; Hypertension; Indoles; Patient Compliance; Time Factors; Vasodilator Agents; Verapamil | 1999 |
Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Blood Pressure; Calcium Channel Blockers; Chronotherapy; Delayed-Action Preparations; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Nifedipine; Randomized Controlled Trials as Topic; Retrospective Studies; Verapamil | 2000 |
Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Atrial Fibrillation; Bradycardia; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Chloride; Combined Modality Therapy; Counterpulsation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Injections, Intravenous; Liver Cirrhosis; Pacemaker, Artificial; Shock, Cardiogenic; Tachycardia, Supraventricular; Vasodilator Agents; Verapamil | 2000 |
Pharmacological rate control of atrial fibrillation.
Topics: Amiodarone; Atenolol; Atrial Fibrillation; Cardiotonic Agents; Digoxin; Diltiazem; Heart Rate; Humans; Metoprolol; Randomized Controlled Trials as Topic; Verapamil | 2004 |
[Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Enalapril; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Myocardial Ischemia; Nifedipine; Perindopril; Placebos; Risk Factors; Surveys and Questionnaires; Time Factors; Vasodilator Agents; Verapamil | 2005 |
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Carotid Artery Diseases; Carotid Artery, Common; Chlorthalidone; Drug Therapy, Combination; Female; Fosinopril; Humans; Hypertension; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Ultrasonography; Vasodilator Agents; Verapamil | 2005 |
Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blockers; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hypertension; Indoles; Middle Aged; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Sympathetic Nervous System; Verapamil | 2008 |
58 trial(s) available for verapamil and atenolol
| Article | Year |
|---|---|
Left ventricular mass regression in elderly hypertensives.
Topics: Aging; Atenolol; Blood Pressure; Coronary Circulation; Delayed-Action Preparations; Echocardiography; Heart; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Verapamil | 1992 |
Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Double-Blind Method; Drug Combinations; Humans; Hypertension; Metoprolol; Middle Aged; Monitoring, Physiologic; Office Visits; Verapamil | 1992 |
Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen.
Topics: Adult; Antihypertensive Agents; Atenolol; Double-Blind Method; Enalapril; Exercise Test; Humans; Hypertension; Male; Physical Endurance; Sports; Verapamil | 1991 |
Effects of verapamil and atenolol on exercise tolerance in 5,000 m cross-country running: a double-blind cross-over study in normal humans.
Topics: Adult; Atenolol; Blood Pressure; Double-Blind Method; Fatigue; Heart Rate; Humans; Male; Physical Endurance; Running; Verapamil | 1990 |
A comparison of sustained release verapamil versus atenolol for 24 h protection from exercise-induced angina pectoris.
Topics: Angina Pectoris; Atenolol; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Exercise Test; Female; Humans; Male; Middle Aged; Verapamil | 1991 |
The effect of verapamil on cardiac sympathetic function.
Topics: Adult; Atenolol; Blood Pressure; Calcium; Heart Rate; Humans; Injections, Intravenous; Male; Myocardial Contraction; Norepinephrine; Premedication; Single-Blind Method; Stimulation, Chemical; Time Factors; Verapamil | 1991 |
[The prevalence of arrhythmias and repolarization changes in patients with mild or moderate essential hypertension undergoing an exercise test. Their variations with different antihypertensive treatments].
Topics: Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Echocardiography; Exercise Test; Humans; Hypertension; Middle Aged; Physical Exertion; Prevalence; Verapamil; Xipamide | 1990 |
The effects of antihypertensive therapy on left ventricular mass in elderly patients.
Topics: Atenolol; Blood Pressure; Cardiomegaly; Double-Blind Method; Echocardiography; Gated Blood-Pool Imaging; Hemodynamics; Humans; Hypertension; Middle Aged; Randomized Controlled Trials as Topic; Verapamil | 1990 |
Influence of left ventricular mass regression on cardiac function in hypertensive elderly individuals.
Topics: Aged; Atenolol; Cardiomegaly; Double-Blind Method; Humans; Hypertension; Middle Aged; Physical Exertion; Ventricular Function, Left; Ventricular Outflow Obstruction; Verapamil | 1990 |
Special considerations in the elderly patient.
Topics: Age Factors; Aged; Aging; Atenolol; Blood Pressure; Cardiac Output; Cardiomegaly; Chlorthalidone; Dose-Response Relationship, Drug; Echocardiography; Humans; Hypertension; Middle Aged; Myocardial Contraction; Risk Factors; Verapamil | 1990 |
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.
Topics: Adult; Aged; Atenolol; Black People; Captopril; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renin; Supination; Verapamil | 1990 |
Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.
Topics: Age Factors; Antihypertensive Agents; Atenolol; Black or African American; Black People; Captopril; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Quality of Life; Randomized Controlled Trials as Topic; Sex Factors; Verapamil | 1990 |
Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.
Topics: Adrenergic beta-Agonists; Aged; Atenolol; Atrial Fibrillation; Chronic Disease; Digitalis Glycosides; Exercise Test; Female; Heart Rate; Humans; Lactates; Male; Middle Aged; Propanolamines; Verapamil; Xamoterol | 1989 |
Effect of verapamil on systemic and brachial artery hemodynamics in normal humans: comparison with effect of atenolol.
Topics: Adult; Aorta, Thoracic; Atenolol; Blood Pressure; Brachial Artery; Delayed-Action Preparations; Echocardiography; Hemodynamics; Humans; Male; Regional Blood Flow; Rheology; Time Factors; Verapamil | 1989 |
Failure of oral atenolol and verapamil to increase the capacity and duration of exercise in patients in sinus rhythm with mitral stenosis.
Topics: Administration, Oral; Adolescent; Adult; Atenolol; Blood Pressure; Child; Exercise Test; Female; Heart Rate; Humans; Male; Mitral Valve Stenosis; Prospective Studies; Random Allocation; Verapamil | 1989 |
Celiprolol and verapamil in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Celiprolol; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Propanolamines; Random Allocation; Verapamil | 1988 |
Effect of calcium channel blockade and beta-adrenoceptor blockade on short graded and single-level endurance exercises in normal men.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Calcium Channel Blockers; Exercise; Heart Rate; Humans; Male; Oxygen Consumption; Physical Endurance; Physical Exertion; Reference Values; Respiration; Self Concept; Time Factors; Verapamil | 1988 |
[Effects of chronic administration of several calcium antagonists on pituitary release of TSH].
Topics: Adult; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Humans; Hypertension; Male; Middle Aged; Nicardipine; Nifedipine; Pituitary Gland, Anterior; Random Allocation; Thyrotropin; Time Factors; Verapamil | 1987 |
[Verapamil and nitrendipine in beta blocker-resistant hypertensive patients].
Topics: Atenolol; Calcium Channel Blockers; Drug Resistance; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Nitrendipine; Verapamil | 1985 |
[Comparative effect of atenolol and verapamil in exertion angina. A single-blind crossed study with computerized exercise test].
Topics: Angina Pectoris; Atenolol; Clinical Trials as Topic; Computers; Exercise Test; Humans; Male; Middle Aged; Verapamil | 1987 |
Comparative study of the antihypertensive effect of verapamil and atenolol.
Topics: Adult; Aged; Atenolol; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Echocardiography; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Myocardial Contraction; Stroke Volume; Verapamil | 1986 |
A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Verapamil | 1987 |
Verapamil in essential hypertension: a comparison with atenolol plus hydralazine.
Topics: Adult; Aged; Atenolol; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Electrocardiography; Female; Heart Rate; Humans; Hydralazine; Hypertension; Male; Middle Aged; Random Allocation; Verapamil | 1987 |
Combined therapy with Ca-antagonists and beta-adrenergic receptor blocking agents in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Blood Pressure; Chronic Disease; Drug Therapy, Combination; Exercise Test; Heart Rate; Humans; Middle Aged; Nitroglycerin; Stroke Volume; Verapamil | 1984 |
Pharmacological effects on coronary haemodynamics. A comparative study between atenolol, verapamil, nifedipine and carbocromen.
Topics: Atenolol; Chromonar; Coronary Circulation; Coronary Disease; Coumarins; Hemodynamics; Humans; Nifedipine; Oxygen Consumption; Propanolamines; Pyridines; Verapamil | 1981 |
Variations in magnesium and zinc in hypertensive patients receiving different treatments.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Captopril; Cholesterol, HDL; Erythrocytes; Female; Humans; Hypertension; Magnesium; Male; Middle Aged; Time Factors; Verapamil; Zinc | 1995 |
[Effect of 3 hypertensive++ agents on ventricular geometry and function].
Topics: Atenolol; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Prevalence; Ventricular Function, Left; Verapamil; Xipamide | 1995 |
Comparative effects of quinapril, atenolol, and verapamil on blood pressure and forearm hemodynamics during handgrip exercise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Cross-Over Studies; Double-Blind Method; Exercise; Forearm; Heart Rate; Humans; Hypertension; Isoquinolines; Middle Aged; Quinapril; Tetrahydroisoquinolines; Vascular Resistance; Verapamil | 1994 |
Effects of quinapril and verapamil versus atenolol on blood pressure during dynamic leg exercise.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Pressure; Double-Blind Method; Exercise; Humans; Hypertension; Isoquinolines; Leg; Middle Aged; Quinapril; Tetrahydroisoquinolines; Verapamil | 1993 |
Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Tolerance; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Lisinopril; Male; Middle Aged; Safety; Verapamil | 1997 |
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Black People; Blood Pressure; Calcium Channel Blockers; Creatinine; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Random Allocation; Verapamil | 1997 |
[Changes in the quality of life influenced by treatment of primary arterial hypertension].
Topics: Adult; Antihypertensive Agents; Atenolol; Enalapril; Humans; Hypertension; Male; Middle Aged; Quality of Life; Verapamil | 1997 |
Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Coronary Disease; Electrocardiography; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Statistics, Nonparametric; Vasodilator Agents; Verapamil | 1998 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; Humans; Hydrochlorothiazide; Hypertension; Middle Aged; Myocardial Infarction; Verapamil | 1998 |
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; Calcium Channel Blockers; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Humans; Male; Middle Aged; Treatment Outcome; Verapamil | 1999 |
Influence of beta-blockers on melatonin release.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Carbazoles; Carvedilol; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Hemodynamics; Humans; Male; Melatonin; Propanolamines; Propranolol; Stereoisomerism; Verapamil | 1999 |
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Quality of Life; Treatment Outcome; Verapamil | 2000 |
Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Diet, Sodium-Restricted; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Male; Middle Aged; Monitoring, Physiologic; Proteinuria; Time Factors; Verapamil | 2001 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Electrocardiography, Ambulatory; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Ischemia; Treatment Outcome; Verapamil | 2001 |
Effective blood pressure treatment improves LDL-cholesterol susceptibility to oxidation in patients with essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Indoles; Male; Malondialdehyde; Middle Aged; Nifedipine; Oxidative Stress; Thiobarbituric Acid Reactive Substances; Verapamil | 2001 |
Metabolic effects of combined antihypertensive treatment in patients with essential hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Glucose; Cholesterol; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hemodynamics; Humans; Hypertension; Indoles; Insulin; Insulin Secretion; Male; Middle Aged; Nifedipine; Verapamil | 2002 |
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biomarkers; Blood Glucose; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; Diastole; Diuretics; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Indoles; Male; Middle Aged; Patient Compliance; Systole; Treatment Outcome; Vasodilator Agents; Verapamil | 2003 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Diuretics; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Indoles; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Treatment Outcome; Verapamil | 2003 |
Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up.
Topics: Adrenergic beta-Antagonists; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Atenolol; Cyclohexanecarboxylic Acids; Female; Follow-Up Studies; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Migraine with Aura; Migraine without Aura; Pizotyline; Propranolol; Tension-Type Headache; Valproic Acid; Vasodilator Agents; Verapamil; Weight Gain | 2005 |
Depressive symptoms in coronary artery disease patients after hypertension treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Coronary Artery Disease; Depression; Female; Humans; Male; Surveys and Questionnaires; Treatment Outcome; Verapamil | 2006 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Diastole; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Treatment Outcome; Verapamil | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Hispanic or Latino; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertrophy, Left Ventricular; Indoles; Ischemic Attack, Transient; Male; Myocardial Revascularization; Residence Characteristics; Risk Factors; Stroke; Systole; Verapamil | 2006 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studies; Comorbidity; Coronary Artery Disease; Female; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Obesity; Outcome and Process Assessment, Health Care; Risk Factors; Sex Distribution; Survival Analysis; United States; Vasodilator Agents; Verapamil | 2007 |
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Confidence Intervals; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterozygote; Humans; Hypertension; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Probability; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome; Verapamil | 2008 |
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Calcium Channel Blockers; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Indoles; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk; Single-Blind Method; Stroke; Verapamil | 2008 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; Female; Humans; Hypertension; Male; Myocardial Infarction; Prognosis; Stroke; Treatment Outcome; Verapamil | 2009 |
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hypertension; Male; Middle Aged; Nitric Oxide Synthase Type III; Pharmacogenetics; Verapamil | 2009 |
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertension; Indoles; Male; Mental Health; Middle Aged; Odds Ratio; Quality of Life; Risk Assessment; Risk Factors; Surveys and Questionnaires; Systole; Time Factors; Treatment Outcome; Verapamil | 2009 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Verapamil | 2007 |
Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Male; Marfan Syndrome; Perindopril; Prospective Studies; Verapamil; Young Adult | 2012 |
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Fasting; Female; Glucose; Haplotypes; Humans; Hydrochlorothiazide; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Prospective Studies; Verapamil | 2013 |
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Indoles; Male; Middle Aged; Monitoring, Ambulatory; Photoperiod; Prospective Studies; Verapamil | 2015 |
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aldehyde Dehydrogenase 1 Family; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Drug Combinations; Drug Resistance; Female; Florida; Genome-Wide Association Study; Georgia; Humans; Hydrochlorothiazide; Hypertension; Indoles; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies; Retinal Dehydrogenase; Risk Factors; Sodium Chloride Symporter Inhibitors; Treatment Outcome; Vasodilator Agents; Verapamil; Young Adult | 2017 |
139 other study(ies) available for verapamil and atenolol
| Article | Year |
|---|---|
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
Topics: Absorption; Adsorption; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Permeability; Pharmacokinetics; Spectrophotometry, Ultraviolet | 1998 |
SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.
Topics: Humans; Intestinal Absorption; Liposomes; Pharmaceutical Preparations; Pharmacokinetics; Predictive Value of Tests; Surface Plasmon Resonance | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Cell Line; Cell Survival; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Models, Molecular; Molecular Structure; Pyridines; Reverse Transcriptase Inhibitors; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship | 2011 |
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Enzyme Inhibitors; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Permeability; Quinazolines; Stroke | 2012 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Survival; Chickens; Humans; Imidazoles; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Models, Molecular; Neurons; Small Molecule Libraries; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship | 2012 |
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Blood-Brain Barrier; Cell Death; Cell Differentiation; Cell Membrane Permeability; Cells, Cultured; Glycogen Synthase Kinase 3; Hippocampus; Humans; Imines; In Vitro Techniques; Lipopolysaccharides; Membranes, Artificial; Microglia; Models, Molecular; Neural Stem Cells; Neurogenesis; Neurons; Neuroprotective Agents; Nitrites; Protein Binding; Rats; Structure-Activity Relationship; Substrate Specificity; Swine; Thiadiazoles | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood-Brain Barrier; Cell Survival; Dose-Response Relationship, Drug; Humans; Microwaves; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Oxidopamine; Peroxynitrous Acid; Structure-Activity Relationship; Tyrosine | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Benzothiazoles; Blood-Brain Barrier; Casein Kinase I; Cell Membrane Permeability; Cells, Cultured; DNA-Binding Proteins; Drosophila; Drug Design; Drug Discovery; HEK293 Cells; Heterocyclic Compounds; High-Throughput Screening Assays; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Neurons; Neurotoxicity Syndromes; Phosphorylation; Protein Kinase Inhibitors; Substrate Specificity | 2014 |
Straightforward entry to pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones and their ADME properties.
Topics: Caco-2 Cells; Carboxylic Acids; Cell Membrane Permeability; Esterification; Half-Life; Humans; Microsomes, Liver; Pyrimidinones; Solubility | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Indans; Inhibitory Concentration 50; Ligands; Peptide Fragments; Permeability; Protein Aggregates | 2014 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain Barrier; Cholinesterase Inhibitors; Humans; In Vitro Techniques; Molecular Structure | 2015 |
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line; Chagas Disease; Disease Models, Animal; Leishmania donovani; Mice; Mice, Inbred BALB C; Nitroreductases; Parasitic Sensitivity Tests; Prodrugs; Protein Structure, Tertiary; Protozoan Proteins; Rats; Sterol 14-Demethylase; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Trypanosoma cruzi | 2015 |
3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
Topics: Animals; Cell Line; Chagas Disease; Dose-Response Relationship, Drug; Humans; Leishmania donovani; Mice; Mice, Inbred BALB C; Molecular Structure; Parasitic Sensitivity Tests; Piperazines; Rats; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Trypanosoma cruzi | 2015 |
Design, synthesis and biological evaluation of tricyclic diterpene derivatives as novel neuroprotective agents against ischemic brain injury.
Topics: Animals; Brain Injuries; Cell Survival; Diterpenes; Dose-Response Relationship, Drug; Drug Design; Glutamic Acid; Molecular Structure; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2015 |
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Benzamides; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Microsomes, Liver; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Permeability; Phenylthiohydantoin; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Tosyl Compounds | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; Cholinesterase Inhibitors; Drug Design; Glutathione; Humans; Quinolines; Reactive Oxygen Species | 2017 |
Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease.
Topics: Animals; Antiviral Agents; Aza Compounds; Blood Proteins; Carbamates; Cell Line; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Esters; Humans; Hydrolysis; Mice; Microsomes, Liver; Models, Molecular; Norovirus; Prodrugs; Protein Binding; Pyrrolidines; Stereoisomerism; Structure-Activity Relationship; Viral Proteins | 2017 |
Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Indoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Neural Stem Cells; Neuroprotective Agents; Protein Kinase Inhibitors; Structure-Activity Relationship | 2017 |
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Discovery; Fluorescence Resonance Energy Transfer; Half-Life; Humans; Mass Spectrometry; Mice; Proteins; Proton Magnetic Resonance Spectroscopy; Pyridones; Structure-Activity Relationship; Sulfonamides | 2017 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Diketopiperazines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Matrix Metalloproteinase 2; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2018 |
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Cytochromes c; Mice; Morpholines; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiophenes; Vero Cells | 2018 |
Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Guanidine; Hedgehog Proteins; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; NIH 3T3 Cells; Structure-Activity Relationship; Thiourea | 2018 |
Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory.
Topics: Antioxidants; Benzoxazoles; Cholinesterase Inhibitors; Drug Design; Humans; Learning; Memory; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2019 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Design; Humans; Ligands; Mice; Rats; Rolipram | 2019 |
Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Drug Design; Humans; Oxidative Stress | 2019 |
Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.
Topics: Benzopyrans; Biochemical Phenomena; Green Chemistry Technology; Humans | 2019 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
Topics: | 2019 |
Development of an
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Computer Simulation; Endothelial Cells; Gene Knockout Techniques; Humans; Organic Chemicals; Rats, Transgenic | 2021 |
Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Agents; Benzamides; Cell Cycle Checkpoints; Cell Line; Cell Membrane Permeability; Cell Movement; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; ErbB Receptors; Half-Life; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Rats; Resorcinols; Transplantation, Heterologous | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyrk Kinases; Glycogen Synthase Kinase 3 beta; Harmine; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2021 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Caco-2 Cells; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Neuralgia; Protein Kinases; Protein Serine-Threonine Kinases; Structure-Activity Relationship | 2021 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; Inflammation; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spinal Cord; Tissue Distribution | 2022 |
Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.
Topics: Amidohydrolases; Analgesics; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Monoacylglycerol Lipases; Neuralgia; Semicarbazones | 2022 |
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
Topics: Imidazoles; Ligands; Pyridines; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2022 |
[Comparative studies with propranolol, verapamil and atenolol in hypertensive dialysis patients].
Topics: Atenolol; Humans; Hypertension, Renal; Kidney Failure, Chronic; Propanolamines; Propranolol; Renal Dialysis; Verapamil | 1977 |
Positive inotropic and negative chronotropic effects of (-)-cis-diltiazem in rat isolated atria.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Atenolol; Calcium; Diltiazem; Endothelium, Vascular; Guinea Pigs; Heart Atria; Heart Rate; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Potassium Chloride; Quinazolines; Rats; Rats, Inbred Strains; Stereoisomerism; Verapamil | 1992 |
Exercise and the pharmacokinetics of propranolol, verapamil and atenolol.
Topics: Adult; Atenolol; Exercise; Exercise Test; Female; Heart Rate; Humans; Male; Propranolol; Verapamil | 1992 |
Obstructive left ventricular hypertrophy. Reversibility of outflow tract obstruction by drug therapy.
Topics: Aged; Aged, 80 and over; Atenolol; Echocardiography, Doppler; Female; Humans; Hypertrophy, Left Ventricular; Ventricular Outflow Obstruction; Verapamil | 1992 |
Transport of beta-blockers and calcium antagonists by diffusion in cat myocardium.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Biological Transport; Calcium Channel Blockers; Cats; Diffusion; In Vitro Techniques; Metoprolol; Myocardium; Propranolol; Sucrose; Verapamil | 1991 |
Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose.
Topics: Atenolol; Delayed-Action Preparations; Drug Overdose; Electrocardiography; Emergency Service, Hospital; Female; Heart Block; Humans; Intra-Aortic Balloon Pumping; Middle Aged; Poisoning; Shock, Cardiogenic; Sympathomimetics; Verapamil | 1991 |
Left ventricular hypertrophy in hypertension.
Topics: Aged; Atenolol; Cardiomegaly; Humans; Hypertension; Middle Aged; Placebos; Verapamil | 1990 |
Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture.
Topics: Amiodarone; Animals; Atenolol; Biomarkers; Cardiotonic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; L-Lactate Dehydrogenase; Liver; Male; Microscopy, Electron; Microscopy, Electron, Scanning; Procainamide; Propranolol; Rats; Rats, Inbred Strains; Sotalol; Verapamil | 1990 |
[Enzyme activity of cardiac glycogen metabolism: study of an in situ hypoxia protocol in the rat].
Topics: Animals; Atenolol; Calcium; Cyclic AMP; Enzyme Activation; Female; Glycogen; Glycogen Synthase; Heart; Hypoxia; Myocardium; Phosphorylases; Rats; Rats, Inbred Strains; Verapamil | 1989 |
[Hemodynamic and medicamentous modification of stimulated atrial natriuretic factor secretion].
Topics: Adult; Aged; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Cardiac Catheterization; Cardiac Pacing, Artificial; Coronary Disease; Cyclic GMP; Female; Humans; Male; Middle Aged; Molsidomine; Verapamil | 1989 |
Adrenergic stimulation of sea urchin sperm cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Caffeine; Calcium; Heterocyclic Compounds; Male; Sea Urchins; Sperm Motility; Spermatozoa; Verapamil | 1989 |
Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Drug Therapy, Combination; Drug Tolerance; Female; Heart; Humans; Male; Metoprolol; Middle Aged; Pindolol; Propranolol; Verapamil | 1985 |
Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Calcium Channel Blockers; Calcium Chloride; Digoxin; Diltiazem; Female; Humans; Isoproterenol; Male; Shock, Cardiogenic; Verapamil | 1985 |
The haemodynamic and myocardial contractile effects of celiprolol, atenolol and propranolol in mecamylamine-verapamil pretreated, anaesthetised dogs.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Circulation; Blood Pressure; Celiprolol; Dogs; Female; Heart Rate; Male; Mecamylamine; Myocardial Contraction; Propanolamines; Propranolol; Verapamil | 1985 |
Epinephrine-induced reversal of verapamil's electrophysiologic and therapeutic effects in patients with paroxysmal supraventricular tachycardia.
Topics: Atenolol; Cardiac Pacing, Artificial; Electrophysiology; Epinephrine; Female; Humans; Male; Middle Aged; Recurrence; Stress, Physiological; Tachycardia, Paroxysmal; Tachycardia, Supraventricular; Time Factors; Verapamil | 1989 |
Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.
Topics: Administration, Oral; Aged; Atenolol; Drug Interactions; Drug Therapy, Combination; Female; Hemodynamics; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Time Factors; Verapamil | 1988 |
Sinus arrest caused by atenolol-verapamil combination.
Topics: Adult; Atenolol; Bradycardia; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Heart Arrest; Humans; Male; Verapamil | 1987 |
Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.
Topics: Administration, Oral; Angina Pectoris; Atenolol; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Metabolic Clearance Rate; Metoprolol; Middle Aged; Verapamil | 1985 |
[Comparison between atenolol and verapamil in the treatment of unstable angina].
Topics: Adult; Aged; Angina Pectoris; Angina, Unstable; Arrhythmias, Cardiac; Atenolol; Drug Evaluation; Humans; Male; Middle Aged; Verapamil | 1985 |
[Evaluation of anti-angina therapy by means of the treadmill test].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Bupranolol; Drug Therapy, Combination; Exercise Test; Humans; Isosorbide; Nifedipine; Vasodilator Agents; Verapamil | 1982 |
Drug-induced inhibition of guinea pig platelet aggregation unrelated to their beta-adrenolytic actions.
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Atenolol; Chemical Phenomena; Chemistry, Physical; Guinea Pigs; In Vitro Techniques; Male; Pindolol; Platelet Aggregation; Procaine; Propranolol; Verapamil | 1983 |
Facilitation of calcium blocking and membrane effects by intrinsic sympathomimetic activity.
Topics: Adrenergic beta-Agonists; Animals; Atenolol; Calcium; Depression, Chemical; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Female; Heart Rate; In Vitro Techniques; Myocardial Contraction; Propanolamines; Propranolol; Verapamil; Xamoterol | 1984 |
Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Drug Interactions; Female; Half-Life; Heart Diseases; Heart Rate; Humans; Kinetics; Male; Metoprolol; Propranolol; Verapamil | 1984 |
Cardiac rhythm in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine.
Topics: Adult; Atenolol; Cardiomegaly; Echocardiography; Electrocardiography; Female; Heart Conduction System; Heart Rate; Heart Ventricles; Humans; Hypertension; Male; Middle Aged; Monitoring, Physiologic; Nifedipine; Time Factors; Verapamil | 1983 |
Aldosterone response to antihypertensive treatment.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Dipeptides; Enalapril; Ethanolamines; Humans; Hypertension; Middle Aged; Prazosin; Pyridazines; Renin; Renin-Angiotensin System; Vasodilator Agents; Verapamil | 1982 |
Beta blockers and verapamil: a cautionary tale.
Topics: Adult; Atenolol; Drug Interactions; Drug Therapy, Combination; Heart Block; Humans; Male; Verapamil | 1984 |
Beta blockers and verapamil: a cautionary tale.
Topics: Adult; Aged; Angina Pectoris; Atenolol; Drug Therapy, Combination; Humans; Middle Aged; Verapamil | 1984 |
Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension.
Topics: Adult; Aged; Atenolol; Chlorthalidone; Forearm; Humans; Hypertension; Male; Middle Aged; Nitroprusside; Regional Blood Flow; Vascular Resistance; Vasodilator Agents; Verapamil | 1983 |
[Use of Falicard and Sectral in patients with COPD and ischemic heart disease].
Topics: Angina Pectoris; Atenolol; Coronary Disease; Drug Evaluation; Drug Therapy, Combination; Humans; Lung Diseases, Obstructive; Verapamil | 1983 |
Evaluation of effect of drugs on the exercise ECG.
Topics: Atenolol; Blood Pressure; Cardiovascular Agents; Coronary Disease; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Isosorbide Dinitrate; Male; Middle Aged; Nifedipine; Propranolol; Verapamil | 1981 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disease Models, Animal; Electric Stimulation; Electrocardiography; Encainide; Ethanolamines; Guinea Pigs; Heart; Heart Conduction System; Injections, Intravenous; Male; Metoprolol; Nebivolol; Phenethylamines; Piperidines; Sotalol; Sulfonamides; Ventricular Fibrillation; Verapamil | 1995 |
Investigation and optimisation of the use of micellar electrokinetic chromatography for the analysis of six cardiovascular drugs.
Topics: Amlodipine; Atenolol; Cardiovascular Agents; Chromatography; Diltiazem; Electrochemistry; Hydrogen-Ion Concentration; Kinetics; Micelles; Nicardipine; Nifedipine; Osmosis; Sodium Dodecyl Sulfate; Verapamil | 1995 |
Alterations of binding characteristics of alpha 1-,beta 1-adrenoceptors and Ca2+ binding sites in the myocardium of spontaneously hypertensive rats (SHR) by chronically administered bunazosin, atenolol, ketanserin and verapamil.
Topics: Adrenergic alpha-Antagonists; Animals; Atenolol; Binding Sites; Blood Pressure; Calcium Channels; Heart; In Vitro Techniques; Ketanserin; Kinetics; Myocardium; Norepinephrine; Quinazolines; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Verapamil | 1993 |
[Paroxysmal atrial fibrillation and flutter and "occult" arterial hypertension. The importance of the ambulatory monitoring of the blood pressure. Apropos 2 cases].
Topics: Atenolol; Atrial Fibrillation; Atrial Flutter; Blood Pressure Monitors; Diltiazem; Drug Therapy, Combination; Humans; Hypertension; Lisinopril; Male; Middle Aged; Verapamil | 1993 |
Hemodynamic profile of activation of histamine H3 receptors by R-alpha-methylhistamine in the guinea pig.
Topics: Animals; Atenolol; Guinea Pigs; Hemodynamics; Hexamethonium; Histamine Agonists; Male; Methylhistamines; Prazosin; Receptors, Histamine H3; Verapamil | 1996 |
Cardiovascular collapse due to intravenous verapamil in two patients with persistent atrial tachycardia.
Topics: Adult; Atenolol; Cardiac Output, Low; Female; Furosemide; Humans; Infusions, Intravenous; Male; Middle Aged; Pregnancy; Tachycardia, Ectopic Atrial; Verapamil | 1995 |
[Stable angina pectoris: what is the role of calcium antagonists?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Diltiazem; Drug Therapy, Combination; Felodipine; Humans; Metoprolol; Multicenter Studies as Topic; Nifedipine; Randomized Controlled Trials as Topic; Verapamil | 1997 |
Combined overdose with verapamil and atenolol: treatment with high doses of adrenergic agonists.
Topics: Adrenergic Agonists; Adrenergic beta-Antagonists; Atenolol; Calcium Channel Blockers; Drug Overdose; Humans; Male; Middle Aged; Poisoning; Verapamil | 1998 |
In vitro effects of calcium channel blockers and beta-adrenergic blocking agents on microsomal lipid perocidation and cytochrome p-450 content.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Calcium Channel Blockers; Cytochrome P-450 Enzyme System; Diltiazem; In Vitro Techniques; Lipid Peroxidation; Male; Microsomes, Liver; Nifedipine; Propranolol; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Verapamil | 1999 |
Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning.
Topics: Adolescent; Adult; Amlodipine; Atenolol; Calcium Channel Blockers; Chemotherapy, Adjuvant; Female; Glucose; Hemodynamics; Humans; Insulin; Male; Middle Aged; Suicide, Attempted; Verapamil | 1999 |
Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression.
Topics: Animals; Atenolol; Biological Transport; Cell Line; Cell Membrane Permeability; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Complementary; Erythromycin; Glucose; Humans; Mammals; Mannitol; Mixed Function Oxygenases; Pharmaceutical Preparations; Phenylalanine; Propranolol; Recombinant Proteins; Testosterone; Tumor Cells, Cultured; Verapamil | 2000 |
Cardiovascular action of a cardioselective Ca(2+)channel blocker AH-1058 in conscious dogs assessed by telemetry.
Topics: Animals; Atenolol; Blood Pressure; Bridged Bicyclo Compounds; Calcium Channel Blockers; Cardiovascular System; Consciousness; Disopyramide; Dogs; Heart Rate; Hemodynamics; Male; Piperidines; Substrate Specificity; Telemetry; Ventricular Pressure; Verapamil | 2001 |
The effect of the fast of Ramadan on ambulatory blood pressure in treated hypertensives.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Fasting; Female; Humans; Hydrochlorothiazide; Hypertension; Islam; Male; Middle Aged; Nifedipine; Religion and Medicine; Sleep; Verapamil | 2001 |
[Medicamentous kidney protection in type 2 diabetic patients--is cheaper also more economical? A model calculation for Swiss health care].
Topics: Adult; Antihypertensive Agents; Atenolol; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Costs; Female; Humans; Kidney Failure, Chronic; Kidney Function Tests; Lisinopril; Male; Middle Aged; Models, Economic; Switzerland; Verapamil | 2002 |
[Diagnosis and therapy of stable angina in Russian Federation (International Study ATP - angina treatment pattern)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Body Mass Index; Calcium Channel Blockers; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agents; Humans; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Russia; Sex Factors; Smoking; Time Factors; Vasodilator Agents; Verapamil | 2003 |
Successful treatment with enoximone for severe poisoning with atenolol and verapamil: a case report.
Topics: Adrenergic Agonists; Anti-Arrhythmia Agents; Atenolol; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dopamine; Drug Overdose; Enoximone; Epinephrine; Heart Rate; Humans; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Verapamil | 2004 |
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol.
Topics: Administration, Oral; Atenolol; Biopharmaceutics; Dosage Forms; Humans; Intestinal Absorption; Propranolol; Solubility; Therapeutic Equivalency; Verapamil | 2004 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Verapamil | 2004 |
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Topics: Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Chi-Square Distribution; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Male; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome; Verapamil | 2005 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Humans; Hypertension; Indoles; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Stroke; Verapamil | 2006 |
Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Case-Control Studies; Cohort Studies; Coronary Disease; Delayed-Action Preparations; Female; Hispanic or Latino; Humans; Hypertension; Indoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Systole; Treatment Outcome; Verapamil | 2006 |
[Recommendations for the medical management of aortic complications of Marfan's syndrome].
Topics: Adrenergic beta-Antagonists; Aortic Aneurysm; Aortic Dissection; Atenolol; Bisoprolol; Calcium Channel Blockers; Drug Therapy, Combination; France; Humans; Marfan Syndrome; Societies, Medical; Treatment Outcome; Verapamil | 2006 |
[Characteristics of action of various drugs blocking atrioventricular conduction (beta-blockers, verapamil, diltiazem) in constant fibrillation tachyarrhythmia. Is monotherapy optimal?].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Atrioventricular Node; Calcium Channel Blockers; Diltiazem; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Metoprolol; Middle Aged; Treatment Outcome; Ventricular Fibrillation; Verapamil | 2006 |
Simultaneous determination of ten antiarrhythic drugs and a metabolite in human plasma by liquid chromatography--tandem mass spectrometry.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Chromatography, Liquid; Diltiazem; Humans; Metoprolol; Mexiletine; Molecular Structure; Propanolamines; Propranolol; Reproducibility of Results; Sotalol; Tandem Mass Spectrometry; Verapamil | 2007 |
Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies.
Topics: Animals; Antiprotozoal Agents; Atenolol; Buffers; Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Intestinal Mucosa; Male; Molecular Structure; Naphthoquinones; Perfusion; Permeability; Propranolol; Quinidine; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Verapamil | 2007 |
Ivabradine: new drug. Best avoided in stable angina.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Benzazepines; Calcium Channel Blockers; Cost-Benefit Analysis; Drug Approval; Europe; Humans; Randomized Controlled Trials as Topic; Verapamil | 2007 |
Hypertension treatment: how important is consistency of effect?
Topics: Antihypertensive Agents; Atenolol; Blood Pressure Determination; Cardiovascular Diseases; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Male; Patient Compliance; Prognosis; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome; Verapamil | 2007 |
The effect of Ramadan fasting on ambulatory blood pressure in hypertensive patients using combination drug therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Drug Therapy, Combination; Fasting; Female; Humans; Hydrochlorothiazide; Hypertension; Islam; Male; Middle Aged; Nifedipine; Religion and Medicine; Verapamil | 2008 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; Databases, Factual; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Indoles; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Stroke; United States; Verapamil | 2008 |
Absorption barriers in the rat intestinal mucosa. 3: Effects of polyethoxylated solubilizing agents on drug permeation and metabolism.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Calcium Channel Blockers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Excipients; In Vitro Techniques; Indicators and Reagents; Intestinal Absorption; Intestinal Mucosa; Male; Mass Spectrometry; Microsomes; Permeability; Pharmaceutical Preparations; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Verapamil | 2010 |
Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism.
Topics: Acridines; Adrenergic beta-Antagonists; Algorithms; Animals; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Computer Simulation; Cyclosporins; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Intestinal Absorption; Intestinal Mucosa; Ketoconazole; Models, Statistical; Pharmaceutical Preparations; Rats; Tetrahydroisoquinolines; Verapamil | 2010 |
Pharmacological treatment of electrical storm in cathecolaminergic polymorphic ventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Atenolol; Defibrillators, Implantable; Drug Therapy, Combination; Electrocardiography; Exercise Test; Humans; Male; Nadolol; Quality of Life; Syncope; Tachycardia, Ventricular; Verapamil | 2010 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coronary Artery Disease; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Male; Randomized Controlled Trials as Topic; Verapamil | 2009 |
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atenolol; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Female; Genotype; Haplotypes; Heterozygote; Humans; Male; Odds Ratio; Polymorphism, Single Nucleotide; Verapamil | 2009 |
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Diabetes Mellitus; Humans; Hypertension; Incidence; Prognosis; Systole; Verapamil | 2010 |
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Topics: Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Channel Blockers; Case-Control Studies; Coronary Artery Disease; DNA; Female; Genotype; Humans; Hypertension; Liver X Receptors; Male; Orphan Nuclear Receptors; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Verapamil | 2011 |
Pharmacophore modeling for hERG channel facilitation.
Topics: Animals; Atenolol; Chlorpheniramine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Haloperidol; Humans; Hydrophobic and Hydrophilic Interactions; Imipramine; Metoprolol; Nortriptyline; Potassium Channel Blockers; Promethazine; Propranolol; Quantitative Structure-Activity Relationship; Sotalol; Terfenadine; Verapamil; Xenopus laevis | 2012 |
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
Topics: Adult; Alleles; Atenolol; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Female; Genetic Predisposition to Disease; Haplotypes; Humans; Linkage Disequilibrium; Liver; Male; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Protein Isoforms; Randomized Controlled Trials as Topic; RNA Splicing; RNA, Messenger; Sex Characteristics; Verapamil | 2012 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Female; G-Protein-Coupled Receptor Kinase 4; Genotype; Haplotypes; Humans; Hydrochlorothiazide; Hypertension; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome; Verapamil | 2012 |
Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats.
Topics: Adrenergic beta-Antagonists; Animals; Arterial Pressure; Atenolol; Benzopyrans; Blood Pressure; Calcium Channel Blockers; Carbazoles; Carvedilol; Denervation; Dose-Response Relationship, Drug; Ethanolamines; Heart Rate; Male; Nebivolol; Propanolamines; Rats; Rats, Wistar; Sinoatrial Node; Verapamil | 2013 |
S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats.
Topics: Animals; Atenolol; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Claudin-5; Cytokines; Infarction, Middle Cerebral Artery; Male; Matrix Metalloproteinase 9; Neuroprotective Agents; Occludin; Pyrrolidines; Rats, Sprague-Dawley; Stroke; Verapamil | 2017 |
High-throughput quantification of ten antiarrhythmic drugs in human plasma using UPLC-MS/MS.
Topics: Anti-Arrhythmia Agents; Atenolol; Bisoprolol; Carvedilol; Chromatography, High Pressure Liquid; Diltiazem; Flecainide; High-Throughput Screening Assays; Humans; Lidocaine; Metoprolol; Propranolol; Reproducibility of Results; Sotalol; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Verapamil | 2019 |
The cardiac work-loop technique: An in vitro model for identifying and profiling drug-induced changes in inotropy using rat papillary muscles.
Topics: Animals; Anthropometry; Atenolol; Cardiotonic Agents; Digoxin; Dobutamine; Electric Stimulation; Flecainide; In Vitro Techniques; Isometric Contraction; Isoproterenol; Male; Myocardial Contraction; Papillary Muscles; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Verapamil | 2020 |
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Proportional Hazards Models; Randomized Controlled Trials as Topic; Sex Factors; Verapamil | 2021 |